DWCM News!
Direct Wireless Communications, Inc. Announces the Appointment of David Cooper, M.D., Ph.D. to the Board of Directors and the Management Team
PR Newswire - November 03, 2003 08:04
WACO, Texas, Nov 3, 2003 /PRNewswire-FirstCall via COMTEX/ -- Direct Wireless Communications, Inc. (OTC Bulletin Board: DWCM), today announced the appointment of David Cooper, M.D., Ph.D. to the Company's Board of Directors. In addition, Dr. Cooper will assume the position of President and Chief Medical Officer of the Company.
Dr. Cooper was the former Chief Science Officer and Chief Operating Officer of the Quest Diagnostics, Nichols Institute, in San Juan Capistrano, California. While at Quest Diagnostics, Dr. Cooper coordinated the Nichols Institute's move to an ISO 9001 Company, expanded their HIV and Genetic Testing, and reorganized the Nichols Institute Research and Test Development efforts into a clinical specialty focus. Dr. Cooper also assisted in opening new markets in Asia, South America and Europe for Quest Diagnostics, Nichols Institute. After leaving Quest Diagnostics, Nichols Institute, Dr. Cooper served as Vice President and Chief Science Officer at diaDexus in Santa Clara, California. Most recently, Dr. Cooper held the position of Chief Medical Officer of NimbleGen Systems. While at NimbleGen Systems, Dr. Cooper established NimbleGen Systems of Iceland, LLC, which currently manufactures custom DNA arrays and related services to the scientific research marketplace worldwide. Dr. Cooper also served as Senior Scientific Advisor to Visible Genetics, Inc. of Toronto, Canada, where he assisted with the development of the FDA approved Tru-Gene HIV genotyping system. In addition, Dr. Cooper's experience also includes serving extensively as a consultant and on various science and medical advisory boards in the fields of diagnostics and biotechnology nationally and internationally.
In academia, Dr. Cooper held tenured Pathology faculty positions at Duke University Medical Center and the University of Pittsburgh Medical Center. While at the University of Pittsburgh, he founded the first division of Molecular Pathology in the United States, assisted in founding and served as the first Chair of the Association for Molecular Pathology (AMP), and was editor and founder of the journal, Molecular Diagnosis -- a journal devoted to the understanding of human disease through the clinical application of molecular biology. His academic honors include the prestigious Lichfield Lectureship, Oxford University, Oxford, England. Dr. Cooper is the author of more than 100 scientific and medical publications in molecular diagnostics and the development of novel gene therapies which were supported by numerous grants including grants from the National Institutes of Health, the American Cancer Society and the Department of Defense Breast Cancer Initiative.
Dr. Cooper received his Ph.D. in Chemistry from the Florida State University, Tallahassee, Florida and his M.D. from the University of Florida, Gainesville, Florida. Dr. Cooper's post-doctoral training was in molecular biology, genetics and immunology while a Fellow at the Fox Chase Cancer Institute, Philadelphia, Pennsylvania and Johns Hopkins University, Baltimore, Maryland. He completed clinical post-graduate training in pediatrics and clinical pathology from the University of Florida, Gainesville, Florida.
Stephen D. Barnhill, M.D., Chairman and Chief Executive Officer of Direct Wireless Communications stated, "We are honored to have a man of Dr. Cooper's experience and expertise on our management team." Dr. Barnhill continued, "We look forward to working with Dr. Cooper as we move to solidify our position in the international diagnostic and drug discovery market."
Dr. Cooper said, "I look forward to working with Dr. Barnhill, one of the pioneers in the field of computational medicine, and the team of world renowned experts being assembled in this Company." Dr. Cooper continued, "The strength of this Company lies in discovery, and utilizing that discovery to create an era of personalized medicine where the focus of diagnosis and treatment is centered on the patient."
Founded in 1971, Quest Diagnostics, Nichols Institute is a world leader in highly specialized laboratory testing. Nichols Institute plays a key role in Quest Diagnostics research and development efforts.
diaDexus was founded in 1997 by SmithKline Beecham (now GlaxoSmithKline) and Incyte Genomics. In April 2000, diaDexus raised over $100 million in additional financing. diaDexus, Inc., a privately held biotechnology company, is focused on the discovery, development, and commercialization of novel, patent protected diagnostic and therapeutic products with high clinical value. diaDexus utilizes genomics and bioinformatics to identify numerous disease-associated molecular targets.
